Icon

ZELBORAF - (240MG)

VEMURAFENIB None
240MG
Less Than $1000 mn
None None
None None
None None
ZELBORAF® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ZELBORAF® is indicated for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.
Yes
ZELBORAF Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
*** *********

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.